Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients

SAN FRANCISCO (August 1, 2009) -- Previously untreated non-small cell lung cancer (NSCLC) patients over the age of 70 respond well to a combination of bevacizumab and erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.

Read the whole article on Science Blog

More from Science Blog